Archives: HowToTreat

Relapsing-Remitting Multiple Sclerosis Treatment: B Cell-Depletion Therapy Shows Promise

Relapsing–remitting MS was once thought to be mediated primarily by T lymphocytes, but emerging evidence points toward B lymphocytes as another potential target. Anti-CD20 monoclonal antibody therapies that deplete B lymphocytes have shown promise in reducing disability, halting new brain lesions, and decreasing the number of treatments required to limit disease activity.